HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles.
Opinion Statement: Gastric and gastroesophageal junction (GEJ) cancers represent the third leading cause of malignancy-associated death worldwide. Approximately 15-20% of these adenocarcinomas overexpress the human epidermal growth factor receptor 2 (HER2), a pro-proliferative receptor tyrosine kina...
| Publicado en: | Current Treatment Options in Oncology Vol. 22; no. 10; pp. 1 - 17 |
|---|---|
| Autores principales: | , |
| Formato: | research Journal Article |
| Publicado: |
Springer Nature
Oct2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=152895623&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 152895623 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15272729 3KHC jtl: Current Treatment Options in Oncology issn: 15272729 maglogo: N pubinfo: dt: Oct2021 vid: 22 iid: 10 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 152895623 152895623 NLM34424404 152895623 10.1007/s11864-021-00884-7 NLM34424404 152895623 ppf: 1 ppct: 16 formats: fmt: @attributes: type: P tig: atl: HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles. aug: au: Grieb, Brian C. Agarwal, Rajiv affil: Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA sug: subj: Stomach Neoplasms Drug Therapy Esophagus Adenocarcinoma Drug Therapy Receptors, Cell Surface Metabolism Receptors, Cell Surface Antineoplastic Agents, Combined Therapeutic Use Human Clinical Trials Drug Combinations Antibodies, Monoclonal Administration and Dosage Fluorouracil Administration and Dosage Adenocarcinoma Metabolism Heterocyclic Compounds Administration and Dosage Paclitaxel Administration and Dosage Drug Resistance, Neoplasm Stomach Neoplasms Metabolism Stomach Neoplasms Cisplatin Administration and Dosage Adenocarcinoma Clinical Assessment Tools ab: Opinion Statement: Gastric and gastroesophageal junction (GEJ) cancers represent the third leading cause of malignancy-associated death worldwide. Approximately 15-20% of these adenocarcinomas overexpress the human epidermal growth factor receptor 2 (HER2), a pro-proliferative receptor tyrosine kinase that has been therapeutically exploited in other disease contexts. The landmark ToGA trial demonstrated that trastuzumab, an anti-HER2 antibody, could improve overall survival for patients with HER2 overexpressing advanced gastric and GEJ adenocarcinomas. In the ensuing decade, great effort has been made to refine and expand this therapeutic strategy through a variety of avenues including optimization of chemotherapy backbones, identifying potential synergy with immune checkpoint inhibition, deployment of alternative HER2-targeted antibodies, use of small molecule inhibitors, and development of HER2-directed antibody drug conjugates. While the results of these efforts have had variable success, they have led to a greater understanding of the mechanisms of both primary and acquired resistance to HER2-directed therapies, laying the groundwork for future investigations. Recently, KEYNOTE-811 and DESTINY-Gastric01 have led to the FDA approvals of pembrolizumab in combination with trastuzumab and chemotherapy in the 1st-line advanced setting and trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki) in the 2nd-line setting, respectively. Herein, we review these significant works as well as discuss the ongoing investigations they have inspired, which aim to find and utilize additional means for targeting HER2 in gastric and GEJ cancers. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|